Comparative Pharmacology
Head-to-head clinical analysis: JENTADUETO XR versus METFORMIN HYDROCHLORIDE AND SITAGLIPTIN PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENTADUETO XR versus METFORMIN HYDROCHLORIDE AND SITAGLIPTIN PHOSPHATE.
JENTADUETO XR vs METFORMIN HYDROCHLORIDE AND SITAGLIPTIN PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JENTADUETO XR combines linagliptin, a DPP-4 inhibitor that increases incretin levels (GLP-1, GIP) leading to glucose-dependent insulin secretion and decreased glucagon release, and metformin, an AMPK activator that decreases hepatic gluconeogenesis, reduces intestinal glucose absorption, and improves insulin sensitivity.
Metformin: Activates AMP-activated protein kinase (AMPK), reducing hepatic glucose production, decreasing intestinal glucose absorption, and improving insulin sensitivity. Sitagliptin: Inhibits dipeptidyl peptidase-4 (DPP-4), increasing incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon release.
The usual starting dose of JENTADUETO XR (empagliflozin/metformin extended-release) is 5 mg/1000 mg orally once daily with the evening meal. Dose can be increased to a maximum of 12.5 mg/2000 mg once daily based on glycemic control and tolerability.
Oral, 50 mg sitagliptin/500 mg metformin twice daily with meals. Maximum: 100 mg sitagliptin/2000 mg metformin per day in divided doses.
None Documented
None Documented
Linagliptin: 12 h (terminal, steady-state) with once-daily dosing providing sustained DPP-4 inhibition. Metformin: 6.2 h (terminal elimination) in patients with normal renal function; prolonged in renal impairment, contraindicated if eGFR < 30 mL/min/1.73 m².
Metformin terminal half-life ~6.2 hours (prolonged in renal impairment; clinical context: dosing adjustment required if eGFR <45 mL/min). Sitagliptin terminal half-life ~12.4 hours (extended in renal impairment; dose adjustment for CrCl <50 mL/min).
Linagliptin: ~90% excreted unchanged in feces via enterohepatic recycling, <5% renally eliminated. Metformin: ~90% eliminated unchanged in urine via glomerular filtration and tubular secretion, <10% in feces.
Metformin is excreted unchanged in urine (90% renal tubular secretion) and feces (10%). Sitagliptin is excreted primarily unchanged in urine (87% renal, 13% fecal via biliary).
Category C
Category A/B
DPP-4 Inhibitor / Biguanide Combination
DPP-4 Inhibitor